West Pharmaceutical Services, Inc.
WST
$251.38
$0.130.05%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 805.00M | 804.60M | 766.50M | 698.00M | 748.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 805.00M | 804.60M | 766.50M | 698.00M | 748.80M |
| Cost of Revenue | 501.10M | 510.30M | 492.60M | 466.10M | 475.20M |
| Gross Profit | 303.90M | 294.30M | 273.90M | 231.90M | 273.60M |
| SG&A Expenses | 107.50M | 101.10M | 94.50M | 86.60M | 83.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 400.00K | 300.00K | 300.00K | 300.00K | 0.00 |
| Total Operating Expenses | 630.80M | 628.80M | 606.50M | 569.30M | 577.00M |
| Operating Income | 174.20M | 175.80M | 160.00M | 128.70M | 171.80M |
| Income Before Tax | 165.40M | 174.00M | 162.00M | 113.90M | 166.90M |
| Income Tax Expenses | 33.30M | 34.00M | 30.20M | 24.10M | 36.80M |
| Earnings from Continuing Operations | 132.10M | 140.00M | 131.80M | 89.80M | 130.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 132.10M | 140.00M | 131.80M | 89.80M | 130.10M |
| EBIT | 174.20M | 175.80M | 160.00M | 128.70M | 171.80M |
| EBITDA | 221.20M | 218.80M | 201.40M | 168.70M | 212.50M |
| EPS Basic | 1.83 | 1.94 | 1.83 | 1.24 | 1.79 |
| Normalized Basic EPS | 1.57 | 1.55 | 1.44 | 1.16 | 1.52 |
| EPS Diluted | 1.82 | 1.92 | 1.82 | 1.23 | 1.78 |
| Normalized Diluted EPS | 1.56 | 1.55 | 1.44 | 1.15 | 1.51 |
| Average Basic Shares Outstanding | 72.30M | 72.20M | 72.20M | 72.50M | 72.70M |
| Average Diluted Shares Outstanding | 72.70M | 72.60M | 72.50M | 73.00M | 73.30M |
| Dividend Per Share | 0.22 | 0.21 | 0.21 | 0.21 | 0.21 |
| Payout Ratio | 11.96% | 10.79% | 11.46% | 16.93% | 11.76% |